Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Pfizer
Emory University
AstraZeneca
Emory University
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Simcha IL-18, Inc.
UNICANCER
Evopoint Biosciences Inc.